KR20220158759A - 사이클로필린 저해제 및 그 용도 - Google Patents

사이클로필린 저해제 및 그 용도 Download PDF

Info

Publication number
KR20220158759A
KR20220158759A KR1020227036425A KR20227036425A KR20220158759A KR 20220158759 A KR20220158759 A KR 20220158759A KR 1020227036425 A KR1020227036425 A KR 1020227036425A KR 20227036425 A KR20227036425 A KR 20227036425A KR 20220158759 A KR20220158759 A KR 20220158759A
Authority
KR
South Korea
Prior art keywords
organ
compound
donor
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227036425A
Other languages
English (en)
Korean (ko)
Inventor
칭-퐁 막
한스 플리리
파슈 마
마이클 필
Original Assignee
파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 filed Critical 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드
Publication of KR20220158759A publication Critical patent/KR20220158759A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020227036425A 2020-03-26 2021-03-25 사이클로필린 저해제 및 그 용도 Withdrawn KR20220158759A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/081296 2020-03-26
CN2020081296 2020-03-26
PCT/CN2021/083015 WO2021190603A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20220158759A true KR20220158759A (ko) 2022-12-01

Family

ID=77891508

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036425A Withdrawn KR20220158759A (ko) 2020-03-26 2021-03-25 사이클로필린 저해제 및 그 용도

Country Status (9)

Country Link
US (1) US20230203099A1 (https=)
EP (1) EP4126903A4 (https=)
JP (1) JP2023518775A (https=)
KR (1) KR20220158759A (https=)
CN (1) CN115315432A (https=)
AU (1) AU2021244763A1 (https=)
CA (1) CA3172689A1 (https=)
TW (1) TW202144378A (https=)
WO (1) WO2021190603A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
AU2020363688A1 (en) 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
US7538084B2 (en) * 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
AU2009276241A1 (en) * 2008-07-30 2010-02-04 Ciclofilin Pharmaceuticals Corp. Nonimmunosuppressive cyclosporine analogue molecules
BR112013014890B1 (pt) * 2010-12-15 2023-10-24 Contravir Pharmaceuticals, Inc Composto análogo de moléculas pertencentes à família ciclosporina, composição farmacêutica compreendendo o mesmo, uso terapêutico ou profilático do referido composto e processos para a preparação dos mesmos
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
CN118324867A (zh) * 2016-05-17 2024-07-12 美国科技环球有限公司 新型环孢菌素衍生物及其用途
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
AU2020363688A1 (en) * 2019-10-12 2022-04-21 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries

Also Published As

Publication number Publication date
EP4126903A1 (en) 2023-02-08
WO2021190603A1 (en) 2021-09-30
CA3172689A1 (en) 2021-09-30
JP2023518775A (ja) 2023-05-08
US20230203099A1 (en) 2023-06-29
AU2021244763A1 (en) 2022-10-06
CN115315432A (zh) 2022-11-08
EP4126903A4 (en) 2024-05-08
TW202144378A (zh) 2021-12-01

Similar Documents

Publication Publication Date Title
KR20220158759A (ko) 사이클로필린 저해제 및 그 용도
JP7776435B2 (ja) シクロフィリン阻害剤およびその使用
AU2022204450A1 (en) Uses of oxygenated cholesterol sulfates (OCS)
US20250288639A1 (en) Treatment and prevention of nephrotoxin-induced kidney injuries
US20160324813A1 (en) Megalin antagonist
US20160113936A1 (en) Methods for modulating monocyte function
TWI917366B (zh) 親環蛋白抑制劑及其用途
EA051978B1 (ru) Ингибиторы циклофилина и их применение
CN102228692A (zh) 钙通道阻断剂在制备拮抗水母毒素心脏毒性药物中的应用
HK40101696A (zh) 肾毒素诱发的肾损伤的治疗和预防
RU2017122329A (ru) Применение соединений ванадия для поддержания нормогликемии у млекопитающего
WO2005107871A2 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
CZ20021562A3 (cs) Pouľití treosulfanu jako prostředku upravujícího předoperační stav pacienta před transplantací kostní dřeně nebo transplantací krevních kmenových buněk
US20050267143A1 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
KR20090128479A (ko) 암 치료를 위한 경요도 절제술 후 방광내 아파지퀀 투여

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202